Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic
Chimeric antigen receptor (CAR) T cells have emerged as an effective therapy for patients with relapsed and refractory haematological malignancies. However, there are many challenges preventing clinical efficacy and thus broader translation of this approach. These hurdles include poor autologous T...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2021-12-01
|
| Series: | European Medical Journal |
| Online Access: | https://www.emjreviews.com/hematology/article/genome-editing-as-a-vehicle-to-drive-successful-chimeric-antigen-receptor-t-cell-therapies-to-the-clinic/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526560891338752 |
|---|---|
| author | Caitlin R Hopkins Joseph A Fraietta |
| author_facet | Caitlin R Hopkins Joseph A Fraietta |
| author_sort | Caitlin R Hopkins |
| collection | DOAJ |
| description |
Chimeric antigen receptor (CAR) T cells have emerged as an effective therapy for patients with relapsed and refractory haematological malignancies. However, there are many challenges preventing clinical efficacy and thus broader translation of this approach. These hurdles include poor autologous T cell fitness, manufacturing issues and lack of conserved tumour-restricted antigens to target. Recent efforts have been directed toward incorporating genome editing technologies to address these challenges and develop potent CAR T cell therapies for a diverse array of haematopoietic cancers. In this review, the authors discuss gene editing strategies that have been employed to augment CAR T cell fitness, generate allogeneic ‘off-the-shelf’ CAR T cell products, and safely target elusive myeloid and T cell cancers that often lack appropriate tumour-specific antigens. |
| format | Article |
| id | doaj-art-426a59949b0f4795a42572cd2404c71e |
| institution | Kabale University |
| issn | 2397-6764 |
| language | English |
| publishDate | 2021-12-01 |
| publisher | European Medical Journal |
| record_format | Article |
| series | European Medical Journal |
| spelling | doaj-art-426a59949b0f4795a42572cd2404c71e2025-01-16T16:31:30ZengEuropean Medical JournalEuropean Medical Journal2397-67642021-12-0110.33590/emj/21-000981Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the ClinicCaitlin R Hopkins0Joseph A Fraietta1Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USADepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA Chimeric antigen receptor (CAR) T cells have emerged as an effective therapy for patients with relapsed and refractory haematological malignancies. However, there are many challenges preventing clinical efficacy and thus broader translation of this approach. These hurdles include poor autologous T cell fitness, manufacturing issues and lack of conserved tumour-restricted antigens to target. Recent efforts have been directed toward incorporating genome editing technologies to address these challenges and develop potent CAR T cell therapies for a diverse array of haematopoietic cancers. In this review, the authors discuss gene editing strategies that have been employed to augment CAR T cell fitness, generate allogeneic ‘off-the-shelf’ CAR T cell products, and safely target elusive myeloid and T cell cancers that often lack appropriate tumour-specific antigens.https://www.emjreviews.com/hematology/article/genome-editing-as-a-vehicle-to-drive-successful-chimeric-antigen-receptor-t-cell-therapies-to-the-clinic/ |
| spellingShingle | Caitlin R Hopkins Joseph A Fraietta Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic European Medical Journal |
| title | Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic |
| title_full | Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic |
| title_fullStr | Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic |
| title_full_unstemmed | Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic |
| title_short | Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic |
| title_sort | genome editing as a vehicle to drive successful chimeric antigen receptor t cell therapies to the clinic |
| url | https://www.emjreviews.com/hematology/article/genome-editing-as-a-vehicle-to-drive-successful-chimeric-antigen-receptor-t-cell-therapies-to-the-clinic/ |
| work_keys_str_mv | AT caitlinrhopkins genomeeditingasavehicletodrivesuccessfulchimericantigenreceptortcelltherapiestotheclinic AT josephafraietta genomeeditingasavehicletodrivesuccessfulchimericantigenreceptortcelltherapiestotheclinic |